Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 6,678 shares at $20.81 ($139K) on 2025-01-07, disclosed to the SEC on 2025-01-08.
Seasonal sale ($139k) by Director — this insider has traded DNLI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.81 | 3,339 | $69K | 50.0% |
| 2 | $20.81 | 3,339 | $69K | 50.0% |
| Total | $20.81 avg | 6,678 | $139K | 100% |
| Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |
| DNLI | SELL | 2024-08-22 | $41K | — | Filing → |